Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from ADC Therapeutics Ltd (ADCT).
The Company recently released a presentation revealing promising initial results from a Phase 2 clinical trial for ZYNLONTA in treating patients with relapsed or refractory marginal zone lymphoma. This information, while not “filed” under SEC regulations, offers exciting insights, potentially impacting the company’s stock as investors and market watchers evaluate these new developments in its clinical advancements.
See more insights into ADCT stock on TipRanks’ Stock Analysis page.